AT&T, Inc. (NYSE:T) has turned on the nation’s most reliable 4G LTE network** in Traverse City, bringing customers the latest generation of wireless network technology. Those who live and work in Grand Traverse and Leelanau counties, including along M-37, M-22, U.S. Highway 31 and County Highway 611 will be most affected by the increased speed. AT&T, Inc. (NYSE:T) stock performance was 0.75% in last session and finished the day at $34.72. Traded volume was 33.31million shares in the last session and the average volume of the stock remained 29.69million shares. The beta of the stock remained 0.43. AT&T, Inc. (NYSE:T) insider ownership is 0.04%.

General Electric Company (NYSE:GE) Aviation is providing technical support to air navigation service provider Airports Authority of India (AAI) to accelerate the deployment of Required Navigation Performance (RNP) flight paths throughout India. General Electric Company (NYSE:GE) rose 1.14 percent to $25.70 Tuesday on volume of 31.15million shares. The intra-day range of the stock was $25.39 to $25.71. General Electric Company (NYSE:GE) has a market capitalization of $258.56billion.

NinePoint Medical, Inc., an emerging leader in the development of medical devices for advanced optical imaging, today announced it has completed a $34 million Series B financing led by Corning Incorporated (NYSE: GLW), along with founding investors Third Rock Ventures and Prospect Venture Partners. The company also announced the addition of three new members to its board of directors: Curt Weinstein from Corning Incorporated (NYSE:GLW), and independent directors Tom Miller and Mark Stautberg. Corning Incorporated (NYSE:GLW)’s stock on Mar 25, 2014 reported a increase of 2.29% to the closing price of $20.06. Its fifty two weeks range is $12.64 -$20.24. The total market capitalization recorded $27.90billion. The overall volume in the last trading session was 21.22million shares. In its share capital, GLW has 1.41billion outstanding shares.

US pharma behemoth Pfizer Inc (NYSE:PFE) says that PROFILE 1014, a Phase III study of anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib), met its primary objective of significantly prolonging progression-free survival (PFS) in previously untreated patients with ALK-positive advanced non-squamous non-small cell lung cancer (NSCLC) when compared to standard platinum-based chemotherapy regimens. On Tuesday, shares of Pfizer Inc. (NYSE:PFE) advanced 1.05% to close the day at $31.82. Company return on investment (ROI) is 10.50% and its monthly performance is recorded as -0.53%. Pfizer Inc. (NYSE:PFE) quarterly revenue growth is 6.07%.